By analyzing the diagram, targets including EGFR, AKT1, MYC, RELA, JUN, MAPK1, FOS, HIF1A, CTNNB1, CCND1, ESR1, TP53, RUNX2, RB1, and CDKN1A may be core targets of the PKSH in the treatment of liver fibrosis (Fig. 3). Here, MAPK1 is linked to Hepatic fibrosis.